Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objective: We evaluated whether patients with histologically verified nonalcoholic fatty liver disease ( NAFLD ) have an impaired incretin effect and hyperglucagonaemia. Methods: Four groups matched for age, sex and body mass index were studied: (i) 10 patients with normal glucose tolerance and NAFLD ; (ii) 10 patients with type 2 diabetes and NAFLD ; (iii) eight patients with type 2 diabetes and no liver disease; and (iv) 10 controls. All participants underwent a 50‐g oral glucose tolerance test ( OGTT ) and an isoglycaemic intravenous glucose infusion ( IIGI ). We determined the incretin effect by relating the beta cell secretory responses during the OGTT and IIGI . Data are presented as medians (interquartile range), and the groups were compared by using the Kruskal–Wallis test. Results: Controls exhibited a higher incretin effect [55% (43–73%)] compared with the remaining three groups ( P < 0.001): 39% (44–71%) in the nondiabetic NAFLD patients, 20% (−5−50%) in NAFLD patients with type 2 diabetes, and 2% (−8−6%) in patients with type 2 diabetes and no liver disease. We found fasting hyperglucagonaemia in NAFLD patients with [7.5 pmol L −1 (6.8–15 pmol L −1 )] and without diabetes [7.5 pmol L −1 (5.0–8.0 pmol L −1 )]. Fasting glucagon levels were lower but similar in patients with type 2 diabetes and no liver disease [4.5 pmol L −1 (3.0–6.0 pmol L −1 )] and controls [3.4 pmol L −1 (1.8–6.0 pmol L −1 )]. All groups had similar glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide responses. Conclusions: Patients with NAFLD have a reduced incretin effect and fasting hyperglucagonaemia, with the latter occurring independently of glucose (in)tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Self-citationThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
Self-citationImpaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
How Useful Is Paracetamol Absorption as a Marker of Gastric Emptying? A Systematic Literature Study
Willems, M., Quartero, A. O., & Numans, M. E. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011935603893 · Cited by 211
Research works printed but not linked: 37
- 10.1111/j.1365-2036.2007.03246.x · DOI · Paper page
- 10.1097/MOT.0b013e3283615d30 · DOI
- 10.1053/jhep.2003.50193 · DOI · Paper page
- 10.1038/nrgastro.2013.182 · DOI · Paper page
- 10.2337/dc06-2247 · DOI · Paper page
- Kalra S, 2013, Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in india (SPRINT), J Assoc Physicians India, 61, 448
- 10.1002/hep.27098 · DOI
- 10.1152/physrev.00034.2006 · DOI · Paper page
- 10.2337/dc11-s227 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01549.x · DOI · Paper page
- 10.1371/journal.pone.0087488 · DOI · Paper page
- 10.1152/ajpendo.00700.2009 · DOI · Paper page
- 10.1152/ajpendo.00529.2004 · DOI · Paper page
- 10.1111/jgh.12981 · DOI
- 10.1002/hep.20701 · DOI · Paper page
- 10.1007/s00125-006-0566-z · DOI · Paper page
- Bablok W, 1988, A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III, J Clin Chem Clin Biochem, 26, 783
- 10.1172/JCI115012 · DOI · Paper page
- 10.2337/diab.43.4.535 · DOI · Paper page
- 10.1016/0167-0115(84)90005-3 · DOI
- Miceli JN, 1979, Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography, Clin Chem, 25, 1002, 10.1093/clinchem/25.6.1002 · DOI · Paper page
- 10.2337/diacare.22.9.1462 · DOI · Paper page
- 10.1002/hep.26988 · DOI · Paper page
- 10.1002/hep.25539 · DOI · Paper page
- 10.1210/jc.2010-0119 · DOI · Paper page
- 10.1002/hep.20734 · DOI · Paper page
- 10.1016/j.regpep.2013.08.002 · DOI
- 10.1152/ajpendo.00571.2005 · DOI · Paper page
- 10.1007/s00125-007-0598-z · DOI
- Shah P, 1999, Impact of lack of suppression of glucagon on glucose tolerance in humans, Am J Physiol, 277, E283
- 10.1016/j.metabol.2005.03.024 · DOI
- 10.1007/s00125-009-1443-3 · DOI · Paper page
- 10.1055/s-2004-821225 · DOI · Paper page
- 10.2337/diabetes.53.2.410 · DOI · Paper page
- 10.1073/pnas.0237106100 · DOI · Paper page
- 10.2337/db11-1605 · DOI · Paper page
- 10.1152/ajpendo.00125.2003 · DOI · Paper page
Cited by
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
“NAFLD patients have fasting hyperglucagonemia when compared to people without NAFLD regardless of diabetes presence [48].”
BackgroundFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Niu, L., Geyer, P. E., Wewer Albrechtsen, N. J., Gluud, L. L., Santos, A., Doll, S., Treit, P. V., Holst, J. J., Knop, F. K., Vilsbøll, T., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188793 · Cited by 285
Self-citationGlucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis
Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes · doi:10.2337/db16-0994 · Cited by 187
Self-citationLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“MASLD is characterised by high plasma concentrations of insulin and glucagon 41 – 44 that contribute to the pathophysiology of this disease.”
Winther-Sørensen, M., Galsgaard, K. D., Santos, A., Trammell, S. A. J., Sulek, K., Kuhre, R. E., Pedersen, J., Andersen, D. B., Hassing, A. S., Dall, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101080 · Cited by 135
Self-citationHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“Patients with MASLD with ( n = 10) or without ( n = 10) T2D showed fasting hyperglucagonaemia 165 that was correlated with elevated plasma levels of amino acids 166 .”
Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
“Interestingly, impaired incretin effects have been observed in patients with NAFLD, both with and without diabetes.(18,19) Consequently, GLP-1 receptor agonists are increasingly recognized as potential agents for treating NAFLD in patients with and without diabetes.”
BackgroundWewer Albrechtsen, N. J., Færch, K., Jensen, T. M., Witte, D. R., Pedersen, J., Mahendran, Y., Jonsson, A. E., Galsgaard, K. D., Winther-Sørensen, M., Torekov, S. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4535-5 · Cited by 119
“Hyperglucagonaemia has also been reported in individuals with fatty liver disease independent of their glycaemic status [35], and this has recently been linked to an increased plasma pool of amino acids including alanine, but excluding the BCAAs isoleucine, leucine and valine [36].”
Self-citation100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
“Glucagon in liver diseases Individuals with cirrhosis have been shown to have hyperglucagonaemia in some studies, although in others this was not evident [102, 103].”
Self-citationEJE PRIZE 2018: A gut feeling about glucagon
Knop, F. K. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0197 · Cited by 47
Self-citationGlucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
“demonstrated that patients with biopsy‐proven NAFLD had hyperglucagonemia regardless of the presence of T2D.(123) In 4937 T2D patients, Wang et al.”
BackgroundInfluentialPatterns of plasma glucagon dynamics do not match metabolic phenotypes in young women
Gar, C., Rottenkolber, M., Sacco, V., Moschko, S., Banning, F., Hesse, N., Popp, D., Hübener, C., Seissler, J., & Lechner, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02014 · Cited by 18
“Hepatic steatosis may even be a cause of hyperglucagonemia, as it disrupts hepatic glucagon sensitivity and probably leads to reactive hypersecretion of the hormone (34).”
Background
Metadata
- Authors
- Junker, A. E., Gluud, L., Holst, J. J., Knop, F. K., & Vilsbøll, T.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2016-01-05
- Volume
- 279
- Issue
- 5
- Pages
- 485-493
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2223377380
- Cited by
- 88
- References
- 14
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Novo Nordisk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.